Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF10B, PRO95780(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13438MR)

This product GTTS-WQ13438MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF10B gene. The antibody can be applied in Colorectal Cancer (CRC) Cancers (CRC) Cancers (CRC) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_003842.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8795
UniProt ID O14763
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF10B, PRO95780(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ13438MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7227MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-G4h-28-F9Z-TpERt CAR(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA FMC63 scFv-G4h-28-F9Z-TpERt CAR
GTTS-WQ2282MR IVTScrip™ mRNA-Anti-C5, ALXN1007(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ALXN1007
GTTS-WQ4293MR IVTScrip™ mRNA-Anti-SNCA, BIIB-054(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BIIB-054
GTTS-WQ14019MR IVTScrip™ mRNA-Anti-IL33, REGN-3500(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA REGN-3500
GTTS-WQ12155MR IVTScrip™ mRNA-Anti-MSLN, MORAb-009(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MORAb-009
GTTS-WQ123MR IVTScrip™ mRNA-Anti-EGFR, 11F8(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA 11F8
GTTS-WQ5107MR IVTScrip™ mRNA-Anti-CD52, Campath-1H(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA Campath-1H
GTTS-WQ15662MR IVTScrip™ mRNA-Anti-EPCAM, VB6-845(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA VB6-845
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW